Linoladiol N

Estradiol hemihydrate, the active ingredient in Linoladiol N, is an estrogen presented as a vaginal formulation for vaginal use. It treats vaginal atrophy and alleviates menopausal symptoms in postmenopausal women.

GNH USA supplies Linoladiol N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Estradiol hemihydrate in Linoladiol N is used in estrogen‑dependent hormone replacement therapy to address menopausal changes.

- Vaginal atrophy: improves thinning and dryness of the vaginal epithelium. - Menopausal symptoms: reduces hot flashes, night sweats and related discomfort. - Urogenital symptoms: alleviates itching, burning and vaginal discharge.

Common Side Effects: - Vaginal irritation: mild burning or discomfort at the application site. - Breast tenderness: transient soreness or swelling of the breasts. - Headache: occasional mild to moderate headache. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Endometrial hyperplasia: abnormal thickening of the uterine lining.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Assess cardiovascular risk: review history of clotting disorders or thrombosis. - Monitor breast changes: report any new lumps, discharge, or pain. - Use lowest effective dose: adjust based on clinical response and tolerability. - Avoid in active estrogen‑dependent malignancy: contraindicated in known breast or endometrial cancer. - Store at room temperature: keep in original packaging, protect from moisture and light.

Estradiol hemihydrate may interact with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Combined oral contraceptives: additive estrogen exposure may increase thrombotic risk. - Tamoxifen therapy: antagonistic effects may reduce therapeutic benefit. - Warfarin: estrogen can potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol levels. - CYP3A4 inducers (e.g., rifampin): may lower estradiol concentrations. - Thyroid hormone replacement: estrogen may alter thyroid‑binding globulin, requiring dose adjustment.